28 julio 2009
Johnson And Johnson Completa la Fase II en Cancer Avanzado de Prostata en EEUU del Yondelis en Solitario el 14 July 2009 .
ET-743 in Men With Advanced Prostate Cancer
This study has been completed.
First Received: November 7, 2003 Last Updated: July 14, 2009
Sponsors and Collaborators: Johnson & Johnson & PharmaMar
Information provided by: Johnson & Johnson
ClinicalTrials.gov Identifier: NCT00072670
This is a study to test the safety and effectiveness of an investigational chemotherapy agent in men with advanced prostate cancer. After a subject meets all entry criteria and signs informed consent he will be enrolled in the study. Participants will be required to attend regular clinic visits to receive study medication and have their status monitored. They will also be required to have PSA levels measured multiple times throughout the study. A detailed explanation can be provided by the investigator conducting this study.
ClinicalTrials.gov processed this record on July 28, 2009
Suscribirse a:
Entradas (Atom)